French study aims to perfect leukemia treatment for kids

NCT ID NCT02716233

Ongoing Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This French study looks at 2,044 children and teens with acute lymphoblastic leukemia (ALL) to find the best way to give the drug pegaspargase. Some patients get one large dose, while others get two smaller doses. The goal is to see which schedule works better and causes fewer side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pegaspargase (ONCASPAR)
What this could lead to: If successful, this could establish a safer and more effective dosing schedule for pegaspargase, improving outcomes for children with ALL.
What could go wrong: This is an observational cohort study, not a randomized controlled trial for all groups, so results may be less definitive. The drug can cause serious side effects like pancreatitis and allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA

Contacts and locations

Locations

CHRU

Besançon, 25030, France
CHU

Amiens, 80054, France
CHU

Angers, 49033, France
CHU

Bordeaux, 33076, France
CHU

Brest, 29609, France
CHU

Caen, 14033, France
CHU

Clermont-Ferrand, 63003, France
CHU

Dijon, 21079, France
CHU

Grenoble, 38043, France
CHU

Lille, 59037, France
CHU

Limoges, 87042, France
CHU

Marseille, 13385, France
CHU

Montpellier, 34295, France
CHU

Nancy, 54511, France
CHU

Nantes, 44093, France
CHU

Nice, 06200, France
CHU

Poitiers, 86000, France
CHU

Reims, 51100, France
CHU

Rennes, 35203, France
CHU

Rouen, 76031, France
CHU

Saint-Etienne, 42270, France
CHU

Strasbourg, 67098, France
CHU

Toulouse, 31059, France
CHU

Tours, 37044, France
CHU Armand Trousseau

Paris, 75012, France
CHU Robert Debré

Paris, 75019, France
CHU Saint Louis

Paris, 75010, France
Chu-Ihope

Lyon, 69373, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.